News | Artificial Heart | March 24, 2016

New Documentary Traces History of SynCardia Total Artificial Heart

Produced by Retro Report for The New York Times, film traces the modern-day SynCardia Heart full circle from its origins as a permanent heart to successfully pioneering use as a bridge to transplant to a new FDA clinical study for permanent use

SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times

March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and modern use of the SynCardia temporary Total Artificial Heart (TAH-t). The 12-minute film, “A Change of Heart,” re-examines this leading story of the past and brings viewers through to today’s news.

This documentary details the development of the SynCardia Total Artificial Heart and its direct predecessor, the Jarvik 7. Like a heart transplant, the TAH-t is the only approved device that eliminates end-stage biventricular (both sides) heart failure. This fatal condition results when the native heart's two ventricles can no longer pump enough blood for a patient to survive.

Through personal stories of surgeons and SynCardia Total Artificial Heart patients, this documentary takes the audience from the first use of a Total Artificial Heart for permanent use in 1982 to today's use as a bridge to a donor heart transplant.

"Use of SynCardia's Total Artificial Heart Technology has gone full circle," said Michael P. Garippa, SynCardia's CEO and president. "The first implants were for permanent use. For the last 30 years the TAH-t has been used as a bridge to transplant. Now we are in an FDA [U.S. Food and Drug Administration] Investigational Device Exemption (IDE) clinical study for 19 destination therapy patients who do not qualify for a donor heart transplant."

"This study is generating data on the effective use of the SynCardia Heart as a way for patients to recover from heart failure and continue with a near-normal lifestyle without a human heart," Garippa said.

The 70cc SynCardia Total Artificial Heart, when used for destination therapy, is an investigational device, limited by United States law to investigational use.

For more information: www.syncardia.com


Related Content

News | Artificial Heart

November 20, 2023 — Student engineers from the University of Bath are on top of the world after winning an international ...

Home November 20, 2023
Home
News | Artificial Heart

November 10, 2023 — BiVACOR, a clinical-stage medical device company developing the Total Artificial Heart (TAH), has ...

Home November 10, 2023
Home
Feature | Artificial Heart | By Francisco Arabia, MD, MBA

The U.S. organ donation system has long been under scrutiny, with questions about fairness in organ allocation and ...

Home July 20, 2023
Home
News | Artificial Heart

July 3, 2023 — Nearly one-third of patients with an implanted device to prevent sudden death have anxiety in the first ...

Home July 03, 2023
Home
News | Artificial Heart

May 1, 2023 — Picard Medical, Inc. (“Picard Medical”), the parent company of SynCardia Systems, LLC (“SynCardia”), a ...

Home May 01, 2023
Home
News | Artificial Heart

April 4, 2023 — A team at the Technical University of Munich (TUM) has induced stem cells to emulate the development of ...

Home April 04, 2023
Home
News | Artificial Heart

March 17, 2023 — More donated hearts could be suitable for transplantation if they are kept functioning within the body ...

Home March 17, 2023
Home
News | Artificial Heart

February 17, 2023 — Allegheny Health Network’s (AHN) Cardiovascular Institute reached a significant milestone in cardiac ...

Home February 17, 2023
Home
News | Artificial Heart

August 15, 2022 — Researchers in the Biomedical Engineering Department at UConn have developed a new cardiac cell ...

Home August 15, 2022
Home
News | Artificial Heart

July 14, 2022 — University of Toronto Engineering researchers have grown a small-scale model of a human left heart ...

Home July 14, 2022
Home
Subscribe Now